Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

45.34 -0.42 (-0.93%)
Streaming Delayed Price Updated: 3:38 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 841,154
Open 45.85
Bid (Size) 45.31 (6)
Ask (Size) 45.36 (6)
Prev. Close 45.76
Today's Range 44.80 - 46.12
52wk Range 33.15 - 65.53
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views
Via Benzinga
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio. 
Via Benzinga

Performance

YTD
+21.25%
+21.25%
1 Month
-12.43%
-12.43%
3 Month
-27.08%
-27.08%
6 Month
-0.32%
-0.32%
1 Year
+16.60%
+16.60%

More News

Read More
Looking Into Halozyme Therapeutics's Recent Short Interest
Via Benzinga
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
A Look Ahead: Halozyme Therapeutics's Earnings Forecast
Via Benzinga
Unveiling 12 Analyst Insights On Halozyme Therapeutics
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
Via Chartmill
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
Via Chartmill
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Via Chartmill
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued.
Via Chartmill
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Via Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
Via Chartmill
Top 2 Health Care Stocks That May Plunge In August
Via Benzinga
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts
Via Benzinga
NASDAQ:HALO is showing good growth, while it is not too expensive.
Via Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
How Is The Market Feeling About Halozyme Therapeutics?
Via Benzinga
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.